Literature DB >> 33575321

Immune Cell Landscape in Gastric Cancer.

Yang Yang1,2,3, Wei He1,2, Zi-Rui Wang1,2, Yu-Jiao Wang1,2, Lan-Lan Li1,4,5,6, Jian-Zhong Lu1,4,5,6, Yan Tao1,4,5,6, Jing Zhang1,4,5,6, Sheng-Jun Fu1,4,5,6, Zhi-Ping Wang1,4,5,6, Shan-Hui Liu1,4,5,6.   

Abstract

BACKGROUND: The tumor-infiltrating immune cells are closely associated with the prognosis of gastric cancer (GC). This article is aimed at determining the composition change of immune cells and immune regulatory factors in GC and normal tissues, depicting their prognosis value in GC, and revealing the relationship between them and GC clinical parameters.
METHODS: We used CIBERSORT to calculate the proportion of 22 immune cells in the GC or normal tissues; a t-test was applied to assess the expression difference of immune cells and immune regulatory factors in normal and GC tissues. The relationship of the immune cells, immune regulatory factors, and GC patients' clinical characteristics was assessed by univariate analysis.
RESULTS: In this study, we found that the proportion of macrophages increased, while plasma cells and monocytes decreased in GC tissues. In these immune fractions, Tregs and naïve B cells were found to be correlated with GC patients' prognosis. Interestingly, the expression of immune regulatory factors was ambiguous with their classical function in GC tissues. For example, TIM-3, FOXP3, and CMTM6 were overexpressed, while CD27 and PD-1 were underexpressed in GC tissues. We also found that IDO1, PD-1, TIGIT, and TIM-3 were highly expressed in high-grade GC tissues, the HERC2 expression level was related to patients' gender, and the TIGIT expression level was sensitive to targeted therapy. Furthermore, our results suggested that the infiltration of Tregs and naive B cells was strongly correlated with the T stage, radiation therapy, targeted molecular therapy, and the expression levels of TIM-3 and FOXP3 in GC.
CONCLUSION: The expression pattern of tumor-infiltrating immune cells and immune regulatory factors was systematically depicted in the GC tumor microenvironment, indicating that individualized treatment based on the tumor-infiltrating immune cells and immune regulatory factors may be beneficial to GC patients.
Copyright © 2021 Yang Yang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33575321      PMCID: PMC7857889          DOI: 10.1155/2021/1930706

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  47 in total

Review 1.  PD-1/PD-L1 Pathway in Breast Cancer.

Authors:  Florian Schütz; Stefan Stefanovic; Luisa Mayer; Alexandra von Au; Christoph Domschke; Christof Sohn
Journal:  Oncol Res Treat       Date:  2017-03-27       Impact factor: 2.825

2.  Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.

Authors:  Xin Liu; Yifan Cao; Ruochen Li; Yong Gu; Yifan Chen; Yangyang Qi; Kunpeng Lv; Jieti Wang; Kuan Yu; Chao Lin; Hao Liu; Heng Zhang; Hongyong He; Lingli Chen; Peipei Zhang; Zhenbin Shen; Jing Qin; Yihong Sun; He Li; Hua Huang; Weijuan Zhang; Jiejie Xu
Journal:  Eur J Cancer       Date:  2020-03-05       Impact factor: 9.162

Review 3.  T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Authors:  Roch Houot; Liora Michal Schultz; Aurélien Marabelle; Holbrook Kohrt
Journal:  Cancer Immunol Res       Date:  2015-10       Impact factor: 11.151

4.  Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer.

Authors:  Xu Lu; Lin Yang; Daxing Yao; Xuan Wu; Jingpo Li; Xuesong Liu; Lijuan Deng; Caiting Huang; Yue Wang; Dan Li; Jingwei Liu
Journal:  Cell Immunol       Date:  2017-01-05       Impact factor: 4.868

Review 5.  Recent advances in cancer immunology and immunology-based anticancer therapies.

Authors:  Sunil Kumar; Reena Vohra Saini; Neeraj Mahindroo
Journal:  Biomed Pharmacother       Date:  2017-12-02       Impact factor: 6.529

Review 6.  Progress in the treatment of advanced gastric cancer.

Authors:  Zheyu Song; Yuanyu Wu; Jiebing Yang; Dingquan Yang; Xuedong Fang
Journal:  Tumour Biol       Date:  2017-07

7.  A Practical Guide to The Cancer Genome Atlas (TCGA).

Authors:  Zhining Wang; Mark A Jensen; Jean Claude Zenklusen
Journal:  Methods Mol Biol       Date:  2016

8.  Targeted therapy in gastric cancer.

Authors:  G Jomrich; S F Schoppmann
Journal:  Eur Surg       Date:  2016-03-07       Impact factor: 0.953

Review 9.  European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment.

Authors:  Franziska M Würfel; Christoph Winterhalter; Peter Trenkwalder; Ralph M Wirtz; Wolfgang Würfel
Journal:  Int J Mol Sci       Date:  2019-04-12       Impact factor: 5.923

View more
  3 in total

1.  Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.

Authors:  Jie Shi; Xu Yang; Xinmei Wang; Yufeng Luo; Weixun Zhou; Hanhuan Luo; Zhaxi Bianba; Zhuoma Nima; Qian Wang; Han Wang; Ruiqian Liao; Quzhen Ciren; Mei Li; Junyi Pang
Journal:  Biomed Res Int       Date:  2022-06-13       Impact factor: 3.246

2.  Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model.

Authors:  Chao Ma; Xin Zhang; Xudong Zhao; Nan Zhang; Sixin Zhou; Yonghui Zhang; Peiyu Li
Journal:  Front Genet       Date:  2021-09-06       Impact factor: 4.599

3.  H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.

Authors:  Jianxin Li; Ting Han; Xin Wang; Yinchun Wang; Xuan Chen; Wangsheng Chen; Qingqiang Yang
Journal:  World J Surg Oncol       Date:  2022-09-14       Impact factor: 3.253

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.